Cinpanemab: Discontinued. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.

Fitusiran is a siRNA targeting AT III, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Dazodalibep is a Fusion protein targeting CD40L, at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Teprotumumab-TRBW is a Monoclonal antibody targeting IGF-1R, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Cariprazine hydrochloride is a Small molecule drug targeting 5-HT1A receptor x 5-HT2A receptor x D2 receptor x D3 receptor, at Approved. This 2026 report.

Atezolizumab is a Monoclonal antibody targeting PDL1, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Nivolumab is a Monoclonal antibody targeting PD-1, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Pembrolizumab is a Monoclonal antibody targeting PD-1, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Retifanlimab is a Monoclonal antibody targeting PD-1, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Benvitimod is a Small molecule drug targeting AHR, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Odronextamab: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.

Cemdisiran is a siRNA targeting C5, at NDA/BLA. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.